Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Mesoblast Limited

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Mesoblast Limited from 2014 to 2023. Over this period, Intra-Cellular Therapies saw a staggering increase in SG&A expenses, growing by nearly 3,900% from 2014 to 2023. In contrast, Mesoblast Limited's expenses remained relatively stable, with a slight decrease of about 2% over the same period.

The data reveals a strategic divergence: Intra-Cellular Therapies appears to be aggressively investing in its operations, while Mesoblast maintains a more conservative approach. This could reflect differing business strategies or market conditions. Notably, the data for 2024 is incomplete, highlighting the dynamic nature of financial forecasting in the biotech sector.